Brief: Oncolytics Biotech Announces Data Demonstrating Proof-Of-Concept For Pelareorep-Proteasome Inhibitor Combination
09/03/2022 12:48
March 9 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® ANNOUNCES PHASE 1B DATA DEMONSTRATING CLINICAL
PROOF-OF-CONCEPT FOR PELAREOREP-PROTEASOME INHIBITOR COMBINATION IN MULTIPLE
MYELOMA IN AN ABSTRACT AT THE AACR ANNUAL MEETING
Source text for Eikon: ID:nCNWRV4v5a
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer